Meningioma mouse models

被引:19
作者
Kalamarides, Michel [1 ,2 ,3 ]
Peyre, Matthieu [1 ,2 ,3 ]
Giovannini, Marco [4 ]
机构
[1] Hop Beaujon, APHP, Dept Neurosurg, Serv Neurochirurg, F-92110 Clichy, France
[2] INSERM, U674, F-75010 Paris, France
[3] Univ Paris 07, Inst Univ Hematol, F-75010 Paris, France
[4] Ctr Neural Tumor Res, House Ear Inst, Los Angeles, CA 90057 USA
关键词
Brain tumor; NF2; Arachnoid; Transgenic mice; Mouse model; SYNTHASE BETA-TRACE; NUDE-MICE; ANAPLASTIC MENINGIOMAS; MALIGNANT MENINGIOMA; TELOMERASE ACTIVITY; ATHYMIC MICE; TUMOR-GROWTH; CELL-LINES; NF2; ESTABLISHMENT;
D O I
10.1007/s11060-010-0331-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery. In order to gain new insights in meningioma biology and develop alternative treatments, several meningioma mouse models have been engineered during the past two decades. As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice. Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported. Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors. These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis. This powerful new technology significantly improves on prior models and may open avenues of investigation never before possible in meningioma research. We present here a review of current meningioma mouse models used in translational therapeutics with associated imaging and preclinical studies.
引用
收藏
页码:325 / 331
页数:7
相关论文
共 50 条
[1]   LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION [J].
Aghi, Manish K. ;
Carter, Bob S. ;
Cosgrove, Garth R. ;
Ojemann, Robert G. ;
Amin-Hanjani, Sepideh ;
Martuza, Robert L. ;
Curry, William T., Jr. ;
Barker, Fred G., II .
NEUROSURGERY, 2009, 64 (01) :56-60
[2]  
AVELLINO AM, 1994, CLIN NEUROPATHOL, V13, P82
[3]   An orthotopic skull base model of malignant meningioma [J].
Baia, Gilson S. ;
Dinca, Eduard B. ;
Ozawa, Tomoko ;
Kimura, Edna T. ;
McDermott, Michael W. ;
James, C. David ;
VandenBerg, Scott R. ;
Lal, Anita .
BRAIN PATHOLOGY, 2008, 18 (02) :172-179
[4]   A genetic strategy to overcome the senescence of primary meningioma cell cultures [J].
Baia, Gilson S. ;
Slocum, Alison L. ;
Hyer, Jeanette D. ;
Misra, Anjan ;
Sehati, Nouzhan ;
VandenBerg, Scott R. ;
Feuerstein, Burt G. ;
Deen, Dennis F. ;
McDermott, Michael W. ;
Lal, Anita .
JOURNAL OF NEURO-ONCOLOGY, 2006, 78 (02) :113-121
[5]   Cerebral meningioangiomatosis in a CD-1 mouse: A case report and comparison with humans and dogs [J].
Balme, Emmanuelle ;
Roth, Daniel Robert ;
Perentes, Elias .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2008, 60 (4-5) :247-251
[6]  
Boldrini L, 2003, INT J MOL MED, V12, P943
[7]   Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas [J].
Boström, J ;
Meyer-Puttlitz, B ;
Wolter, M ;
Blaschke, B ;
Weber, RG ;
Lichter, P ;
Ichimura, K ;
Collins, VP ;
Reifenberger, G .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :661-669
[8]   Establishment of an in vivo meningioma model with human telomerase reverse transcriptase [J].
Cargioli, Theresa G. ;
Ugur, Hasan C. ;
Ramakrishna, Naren ;
Chan, Jennifer ;
Black, Peter M. ;
Carroll, Rona S. .
NEUROSURGERY, 2007, 60 (04) :750-759
[9]  
Chamberlain MC, 2004, NEUROLOGY, V62, pA473
[10]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846